68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Recruiting · NCT06612580 · Interventional (participants receive a specific treatment) · Lead sponsor: First Affiliated Hospital of Fujian Medical University
View the official record on ClinicalTrials.gov →Interventions studied
68Ga-AAZTA-NI-093
What this trial is about
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.
Who can take part
Age range
18 Years to 80 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- confirmed treated or untreated prostate cancer patients;
- signed written consent.
Exclusion criteria
- known allergy against PSMA;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where it is running
1 location listed.
- The First Affiliated Hospital of Fujian Medical University - Fuzhou, Fujian, China